小梁切除术联合丝裂霉素治疗虹膜角膜内皮综合征继发性青光眼

目的：为评价抗青光眼滤过手术联合应用丝裂霉素治疗虹膜角膜内皮（ICE）,综合征继发性青光眼的疗效。方法：对已确诊为ICE综合征,用局部降眼压药眼压控制不良的11例继发青光眼病人实施小梁切除手术,术中使用丝裂霉素,然后对其术后情况进行追踪观察。结果：经6-50个月的随访观察,6例（6只眼,54.5%）眼压控制在21mmHg以下,其中2例须使用局部降眼压药。结论：小梁切除术联合丝裂霉素能一定程度地提高ICE综合征继发性青光眼手术成功率。     

小梁切除联合丝裂霉素C治疗儿童青光眼

目的观察小梁切除术联合丝裂霉素C(MMC)治疗儿童青光眼的疗效和安全性。方法小梁切除术联合MMC治疗儿童青光眼32例(32眼)年龄3～14岁。术后随访时间6～40月(平均18.07±5.81月),对眼压、视力和并发症进行了分析,以KaplanMeier寿命表判断成功率。结果相对成功率标准为:眼压6～21mmHg,不用或用抗青光眼药物,不需要再进行抗青光眼手术,并且未发生严重的并发症。6月累积成功率为85.47%(n=32),12月为76.32%(n=25),24月为64.29%(n=12)。并发症包括浅前房6眼、薄壁滤过泡5眼、滤过泡渗漏3眼、囊样滤过泡2眼、低眼压2眼、滤过泡炎1眼、白内障1眼和视网膜脱离1眼。结论小梁切除术联合MMC可能是治疗儿童青光眼一种有效的方法。然而,MMC术后薄壁滤过泡和滤过泡相关的感染以及其他问题尚需长期随访。     

小梁切除术联合丝裂霉素C治疗难治性青光眼

目的 :探讨小梁切除术联合丝裂霉素C治疗难治性青光眼的效果。方法 :采用小梁切除术联合术中应用丝裂霉素C ,对 3 4例 (4 7眼 )难治性青光眼进行了手术治疗 ;术后进行了 1年的随访。结果 :术后前房均形成良好。术后 1年随访 ,Ⅰ型滤过泡 2 7眼 ,Ⅱ型 19眼 ,Ⅲ型 1眼。术后 1周、 1个月、 6个月、 1年的平均眼压值分别为 10 2 3± 6 41、 12 43± 7 62、 16 0 3± 6 19、 18 5 5± 5 95mmHg。视力增进 2 8眼 ,无变化 19眼。结论 :小梁切除术联合丝裂霉素C是治疗难治性青光眼的有效方法。     

外伤性房角退缩性青光眼小梁切除联合丝裂霉素治疗

目的观察小梁切除术术中联合应用丝裂霉素C（Mitomycin C，MMC）治疗外伤性房角退缩性青光眼的效果。方法小梁切除术联合术中心用MMC治疗外伤性房角退缩性青光眼22例（22眼）。术后对眼压、视力和并发症进行了分析。以Kaplan—Meier寿命表判断成功率。结果成功标准为：不用或用局部抗青光眼药物，眼压在6～21mmHg之间；不需要再进行抗青光眼手术；并且未发生严重的并发症。6月累积成功率为86．36％（n=22），12月为78．57％（n=14），18月为66．67％（n=6）。术后视力与术的相间或稍有提高17例（77．27％），视力下降5例（22．73％）。并发症包括浅前房6眼、溥壁滤过泡3眼、低眼压1眼和白内障1眼。结论小梁切除术联合MMC是治疗外伤性房角退缩性青光眼一种有效的方法。术后大部分病人眼压被控制，保存了有用的视力。     

虹膜睫状体后加小梁切除术联合丝裂霉素治疗晚期青光眼

目的 探讨虹睫状体压后加小梁切除术联合丝理解霉素治疗绝对期青光眼和近绝对期青光眼的疗效。方法 采用以角缘为基底的结膜瓣，１２点钟做小梁切除术，在其两２ｍｍ处七膜睫太体压后术。三个术共分离巩膜瓣后，用０．０２５％线裂霉素棉片置巩膜瓣上下５分钟，生理盐水冲洗后先行虹膜睫状体压后，最后行小梁切除术。结果 共手术２１例，观察２－５年，视力提高１３眼，眼压控制理想，无１例眼球摘除。结论 晚期青光眼在常规手术     

小梁切除联合MMC治疗青光眼的临床观察

目的 探讨小梁切除联合丝裂霉素C治疗青光眼的临床疗效.方法 应用小梁切除术联合丝裂霉素C治疗32例（45眼）各型青光眼,术中一次性使用0.2mg/ml丝裂霉素C,术后随访6-24月,观察其临床疗效及其并发症.结果 术后1月检查,33眼（73.33％）术后视力有不同程度的提高;术后1周测眼压,平均11.20--2.15mmHg,术后6月测眼压,平均16.86mm±3.81mmHg,均较术前有统计学差异;末次随访时,41眼（91.1％）形成弥散扁平的功能性滤过泡;总手术成功41眼（91.1％）.术后主要并发症为：浅前房2眼,前房积血1眼,角膜水肿3眼.讨论 小梁切除联合丝裂霉素C治疗青光眼,可有效地减少青光眼术后滤过道瘢痕的形成,充分降低眼压.该方法不需要特殊设备,并发症少,手术效果好,是一种安全、有效的治疗青光眼方法.     

丝裂霉素联合复合式小梁切除术治疗难治性青光眼疗效

目的:探讨丝裂霉素联合复合式小梁切除术在难治性青光眼患者中的效果.方法:选取我院2014-01/2015-06收治的难治性青光眼患者110例122眼,采用随机数字表法分为观察组55例62眼和对照组55例60眼,均行复合式小梁切除手术治疗,观察组患者术中加用丝裂霉素C.术后随访12mo,对患者眼压及视力进行测量,术前及术后3 mo清晨采集空腹血3 mL,ELISA法其血清维生素B12(VB12)、维生素B6(VB6)、叶酸(FA)及白介素-2(IL-2),白介素-6(IL-6)水平.结果:术前,两组眼压比较无显著性差异(P＞0.05),术后lwk～ 12mo,观察组眼压均显著低于对照组(P＜0.01);术前,两组视力比较无显著性差异(P＞0.05),术后1wk～12mo,观察组视力均显著高于对照组(P＜0.01);术前,两组患者VB12、VB6、FA、IL-2、IL-6比较均无显著性差异(P＞0.05),术后3 mo,观察组VB12、FA、IL-2、IL-6均显著高于对照组(P＜0.05).结论:丝裂霉素C联合复合式小梁切除术治疗难治性青光眼可有效控制眼压、提高视力,改善病情,提高难治性青光眼的治疗成功率.     

小梁切除术联合丝裂霉素C治疗难治性先天性青光眼的临床观察

】     

非穿透小梁切除联合丝裂霉素治疗青光眼

开角型青光眼的手术治疗传统的方法仍是小梁切除，术后浅前房及其它并发症较多。非穿透小梁切除手术(NWS)是目前较新的术式，它能更好地控制眼压及避免穿透手术可能出现的并发症，并使视力迅速恢复，联合应用丝裂霉素C(MMC)减少了术后瘢痕形成，我院自2001年2月以来采用非穿透小梁切除术联合丝裂霉素治疗开角型青光眼42例(42眼)，疗效良好，现报告如下。     

改良小梁切除术联合丝裂霉素C治疗青光眼的临床观察

目的 探讨改良式小梁切除术联合丝裂霉素C治疗青光眼的临床疗效.方法 应用改良式小梁切除术治疗42例64眼各型青光眼,术中一次性使用0.4 mg/ml丝裂霉素C,术后随访6～12月,观察其临床疗效及其并发症.结果 术后1个月检查,58眼(90.6％)术后视力有不同程度的提高;术后1周测眼压,所有病例眼压均有不同程度的下降,有48眼(75.0％)眼压低于21 mm Hg,术后6个月测眼压,54眼(84.4％)低于21 mmHg;末次随访时,56眼(87.5％)形成弥散扁平的功能性滤过泡,8眼(12.5％)为非功能性滤过泡;总手术成功58眼(90.6％),其中完全成功54眼(84.4％),条件成功4眼(6.3％),失败6眼(9.4％).术后主要并发症为:角膜水肿5眼,前房渗出4眼.结论 改良小梁切除术联合丝裂霉素C治疗青光眼,可有效地减少青光眼术后滤过道瘢痕的形成,充分降低眼压.该方法不需要特殊设备,手术时间短,损伤小,并发症少,手术效果好,是一种安全、有效的治疗青光眼方法.     

小梁切除术合并丝裂霉素联合视网膜冷凝治疗新生血管性青光眼

目的：：探讨小梁切除术合并丝裂霉素联合视网膜冷凝治疗新生血管性青光眼的疗效及对患者眼部血流动力学的影响。方法：将45例45眼采用改良小梁切除术联合睫状体视网膜冷凝治疗的新生血管性青光眼患者纳入本研究,观察术后疗效、视力、眼压及并发症等情况,并采用彩色多普勒成像技术检测患者健侧眼与患侧眼术前及术后2 wk的眼部血流动力学指标。结果：术后6 mo手术成功率为84%,功能性滤泡形成率为82%,并发症发生率为27%;术后1、3、6 mo的眼压均较术前显著降低(P<0.05),且术后1、3、6mo的矫正视力较术前显著提高(P<0.05);术后1、3、6mo患侧眼血流动力学参数PSV、EDV、RI均较术前显著改善( P<0.05)。结论：小梁切除术合并丝裂霉素联合视网膜冷凝治疗新生血管性青光眼的手术成功率高,能有效控制患者眼压,改善视力和眼部血流动力学指标。     

丝裂霉素及调整缝线在小梁切除术中的应用

目的 探讨复合小梁切除术的降眼压效果。方法 对58例（78眼）青光眼实施复合小梁切除术,术中在巩膜瓣下放1块0.25mg/ml丝裂毒素C浸润棉片3min.缝合巩膜瓣时增加缝线跨距以备术后断线控制眼压。术后随访眼压、滤过泡及前房情况。结果 全部患眼手术成功,滤过泡形成满意,在术后1周、1月、3月、及6月时眼压控制良好,与术前比P〈0.001。6月时滤过泡均为有功能的滤过泡。并发症主要有早期浅前房、少量前房积血等。结论 术中使用0.25mg/ml丝裂毒素C有利于形成长期有效的滤过泡,结合术后断线可更好地控制眼压,减少浅前房等并发症的发生。     

Trabeculectomy with Ologen implant versus mitomycin C in congenital glaucoma secondary

AIM: To compare the efficacy and safety of collagen matrix implant [Ologen (OLO) implant] versus mitomycin C (MMC) with subscleral trabeculectomy (SST) for the surgical treatment of congenital glaucoma (CG) in Sturge- Weber Syndrome (SWS). METHODS: A prospective comparative randomized study of 20 eyes of 16 patients with CG associated with SWS was divided into two groups. The first group (MMC Group) included 10 eyes that were subjected to SST with MMC. The second group (OLO Group) included 10 eyes that were subjected to trabeculectomy with a collagen matrix implant (OLO implant). Postoperative evaluation included intraocular pressure (IOP) level, bleb evaluation, complications, and the need for further medication or surgical intervention. RESULTS: The mean preoperative IOP was 29±3.16 mm Hg in MMC and 29.8±3.08 mm Hg in OLO eyes. Mean 12-month percentage reduction in IOP was significant in both groups (57.9% and 56.3%). At the end of the 12 postoperative follow-up month, in the MMC Group, 80% of eyes achieved the complete success, 20% of eyes had qualified success with no failed surgery in comparison to OLO Group which 70% of eyes achieved the complete success, 20% of eyes had qualified success with 10% failed surgery. In terms of complications, the MMC Group had a higher rate of complications than the OLO Group in the form of thin polycystic bleb in 6 eyes (60%), blebitis in only one eye (10%) treated with topical antibiotics, shallow anterior chamber in two eyes (20%). CONCLUSION: This study proves that the use of a collagen matrix implant yields equally effective results as MMC when combined with trabeculectomy for the treatment of CG in SWS. Furthermore, OLO implantation is safe and has low incidences of complications.     

Trabeculectomy with brief exposure to mitomycin C

BACKGROUND: To evaluate the safety and efficacy of primary trabeculectomy with brief exposure (15 s) to mitomycin C (MMC) (0.4 mg/mL). METHODS: Medical record review of all patients who underwent primary trabeculectomy with brief exposure to MMC at the Goldschleger Eye Institute in a 4-year period was performed. RESULTS: Sixty-three patients (35 men, mean age of 55 years) underwent trabeculectomy with brief exposure to MMC. Intraocular pressure (IOP) decreased a mean +/- standard deviation of 17.9 +/- 9.6 mmHg from 30.4 +/- 9.5 mmHg preoperatively to 12.5 +/- 6.2 mmHg postoperatively after a mean follow up of 18.3 months (P < 0.001). Number of antiglaucoma medications decreased from 2.9 +/- 1.1 preoperatively to 0.2 +/- 0.4 postoperatively (P < 0.001, paired samples t-test). Complete success, defined as IOP < 18 mmHg without antiglaucoma medication, was achieved in 46 patients (73%) and qualified success, defined as IOP 相似文献   

小梁切除术联合丝裂霉毒C治疗青光眼的临床疗效

目的:探讨小梁切除联合丝裂霉素C(mitomycin C,MMC)治疗青光眼的临床疗效。方法:原发性青光眼患者57例95眼随机分为两组,为小梁切除术联合MMC(T+MMC)组(31例54眼)和小梁切除术(T)组(26例41眼),术后随访4~6mo,观察其前房、滤过泡、眼压及并发症。结果:T+MMC组术后1d平均眼压为11.24±3.73mmH g,较术前眼压明显降低(P<0.01),与T组比较差异无统计学意义(P>0.05)。而末次随访平均眼压为16.15±3.62mmH g,与T组(18.79±5.27mmH g)比较具有统计学差异(P<0.05)。T+MMC组和T组功能性滤过泡形成率分别为94.44%和80.48%,组间差异具有显著统计学意义(P<0.01)。两组偶发前房出血、角膜水肿,均治愈。结论:采用小梁切除术联合MMC治疗青光眼,术后眼压控制及滤过泡形态维持均良好,并发症少。     

Trabeculectomy augmented with mitomycin C application under the scleral flap

AIM—The authors investigated the safety and intraocular pressure (IOP) lowering effectiveness of trabeculectomy augmented with mitomycin C application beneath the scleral flap, and assessed the influence of preoperative risk factors on the surgical outcome.METHODS—A retrospective study of 72 consecutive high risk eyes undergoing trabeculectomy with adjunctive mitomycin C (0.2 mg/ml) applied under the scleral flap for 5 minutes was performed. Each eye was ascribed a score based on the number of preoperative risk factors, and categorised into one of three risk factor groups. Success was described as unqualified where IOP was ? 21 mm Hg without medication and qualified where antiglaucomatous therapy was required to maintain it at such a level. A life table analysis of IOP control was calculated.RESULTS—The mean IOP (SD) fell from a preoperative level of 28.4 (6.9) to a level of 16.63 (8.06) mm Hg at the last follow up (paired Student''s t test: p< 0.0001). Fifty two eyes (72%) were classed as unqualified successes. The survival rates did not differ significantly between different risk factor groups (log rank test: χ² = 0.967, p>0.1). The incidence of postoperative complications compared favourably with reports of mitomycin C application between Tenon''s capsule and the undissected scleral bed.CONCLUSION—The results illustrate that mitomycin C applied beneath the scleral flap during trabeculectomy in high risk eyes is associated with a success rate comparable to other modes of application. The incidence of potentially serious complications such as conjunctival wound leak and prolonged hypotony was lower than previously published data reporting sub-Tenon''s administration of mitomycin C. The number and nature of preoperative risk factors do not appear to influence the surgical outcome. A possible mechanism of action is proposed.